J&J sues over schizophrenia drug generic following patent victory

Janssen filed patent infringement suits in New Jersey and Delaware over proposed copy of blockbuster drug Invega Sustenna | Lawsuits follow appeals court win for J&J in separate action with Teva and Mylan.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

J&J fends off generic schizophrenia drug bids

10 July 2025 Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental health treatment | Appeals court rejects arguments that patent claims would have been obvious to a relevant artisan.

Americas

Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies

10 June 2025 US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and Aurobindo Pharma until 2030s.

Americas

J&J unit could owe biotech $125m over AI-based surgical ‘night vision’ tech

3 June 2025 New York court finds Ethicon breached agreement with ChemImage over advanced imaging technologies | Parties dispute damages for IP ‘impairment’.

More features

Simmons & Simmons patent litigator jumps ship

ITC probes on the rise, but gender parity lags behind

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Philips wins unprecedented trade secret sanctions against Chinese defendants

Womble Bond Dickinson partners jump to rival firm

J&J sues over schizophrenia drug generic following patent victory

More on this story

Editor's picks

Editor's picks

More features